Abstract: GSK126 is a highly selective, S-adenosyl-L-methionine (SAM)-competitive small-molecule inhibitor of the Enhancer of Zeste Homolog 2 (EZH2) methyltransferase, which serves as the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2). While GSK126 has been primarily investigated for its oncological applications, EZH2 is implicated in a broad spectrum of physiological and pathological processes, including neuroinflammation and cardiovascular diseases. This review synthesizes current knowledge on GSK126 based on the provided literature, detailing its pharmacological activity, molecular mechanism of action, structural synthesis, and clinical limitations. By highlighting its potent anti-inflammatory properties and its ability to modulate epigenetic silencing, this review provides insights into the potential repurposing of GSK126 for broader therapeutic applications, including cardiovascular diseases and fibrosis.
1. Introduction
The Polycomb Repressive Complex 2 (PRC2) is a critical epigenetic regulator that controls gene expression and chromatin structure. It functions primarily by catalyzing the mono-, di-, and trimethylation of histone 3 at lysine 27 (H3K27), a process that leads to chromatin compaction and subsequent gene silencing [1]. The core catalytic subunit of the PRC2 complex is the Enhancer of Zeste Homolog 2 (EZH2) [1]. EZH2 plays a vital role in maintaining normal cellular function, but its dysregulation is heavily implicated in various pathological conditions, including oncogenesis, immune disturbances, neuroinflammation, and cardiovascular diseases [2].
Because EZH2 has dual functions that allow it to act as both an oncogene and a tumor suppressor, nuanced pharmacological strategies have been developed to inhibit its activity [1]. GSK126 (also known as GSK2816126) emerged as a highly selective, direct small-molecule inhibitor of EZH2 [1][2]. Although initial clinical trials focused on its anti-cancer properties, the recognition of EZH2 as an epigenetic regulator of cardiovascular development and inflammation opens new avenues for investigating GSK126 in the context of cardiovascular diseases and fibrosis [2].
2. Pharmacological Activity
In the realm of oncology, GSK126 has demonstrated the ability to effectively inhibit the proliferation of EZH2 mutant diffuse large B-cell lymphoma (DLBCL) cell lines [1]. Preclinical models of skin cancer showed that GSK126 significantly increased cell death and reduced epidermal cancer stem cell formation, migration, invasion, and tumor growth [1]. Despite these promising *in vitro* results, a phase 1 clinical trial evaluating GSK126 in patients with refractory non-Hodgkin lymphoma, multiple myeloma, and solid tumors revealed modest clinical efficacy. Out of 22 evaluable patients, only one achieved a partial response, while the majority experienced progressive disease, leading to the termination of the study [1].
Beyond oncology, GSK126 exhibits significant anti-inflammatory pharmacological activity. In *in vivo* models of neuropathic pain and nerve injury, systemic administration of GSK126 successfully ameliorated mechanical and cold allodynia [2]. Treatment with GSK126 reduced the levels of key pro-inflammatory mediators, including interleukin-1α (IL-1α), monocyte chemoattractant protein-1 (MCP-1), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) in damaged nerves [2]. Furthermore, it decreased the protein expression of tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6 in the central nervous system [2]. These potent anti-inflammatory effects highlight its potential utility in treating diseases driven by chronic inflammation, such as cardiovascular and fibrotic disorders.
3. Molecular Mechanism of Action
GSK126 functions as a direct, SAM-competitive inhibitor of the EZH2 methyltransferase [1][2]. During the normal epigenetic methylation process, EZH2 utilizes S-adenosyl-L-methionine (SAM) as a universal methyl donor to transfer methyl groups to the lysine side chains of the target histone [2]. GSK126 produces its inhibitory effects by directly competing with SAM for the binding site on the SET domain of EZH2 [2].
The compound is highly selective, exhibiting a 150-fold increased potency toward EZH2 compared to its homolog EZH1, and a 1000-fold selectivity for EZH2 over 20 other methyltransferases [1]. By blocking EZH2 activity, GSK126 prevents the trimethylation of H3K27 (H3K27me3), thereby preventing chromatin compaction and allowing for the partial reversal of silenced gene expressions [1][2]. In inflammatory contexts, the inhibition of EZH2 by GSK126 has been shown to suppress microglial activation and increase autophagy function by modulating the mammalian target of rapamycin (MTOR)-dependent signaling pathway [2].
4. Structure-Activity Relationship (SAR)
The development and optimization of GSK126 relied on retrosynthetic analysis, a technique used to plan the synthesis of complex molecules by breaking them down into simpler precursor structures [1]. For GSK126, the foundational building block is a halo-indole carboxyl group [1].
The synthesis proceeds by joining this halo-indole carboxyl group with a boronate ester—specifically 1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-piperazine—via a Suzuki–Miyaura cross-coupling reaction [1]. Following this step, amide coupling is utilized to join the resulting intermediate compound with 3-(aminomethyl)-4,6-dimethyl-2(1H)-pyridinone, yielding the final GSK126 molecule [1]. This specific synthesis technique drastically decreased the cost of production, making further research and development of the compound feasible [1].
5. Current Limitations
Despite its high selectivity and potency *in vitro*, GSK126 faces several significant limitations that have hindered its clinical translation. A major pharmacological drawback is its lack of oral bioavailability, which restricts its administration and patient compliance compared to other orally bioavailable EZH2 inhibitors like Valemetostat and UNC1999 [1].
In clinical settings, GSK126 was associated with a high frequency of adverse side effects. During phase 1 trials, the most common side effects included fatigue (53%), nausea (30%), anemia (20%), and vomiting (20%) [1]. The maximum tolerated dose was capped at 2400 mg due to dose-limiting toxicities, specifically elevated liver transaminases observed at the 3000 mg dose level [1].
Furthermore, acquired drug resistance presents a critical challenge. Preclinical studies discovered that the activation of the IGF-1R, PI3K, and MEK pathways is sufficient to cause resistance to SAM-competitive EZH2 inhibitors like GSK126 [1]. Notably, cells that gain resistance to GSK126 also exhibit cross-resistance against other EZH2 inhibitors, such as Tazemetostat, limiting its use as a second-line therapy in relapsed patients [1].
6. Future Perspectives
Although clinical trial data indicated that GSK126 failed to produce a meaningful therapeutic effect as a monotherapy in certain human cancers, it remains a highly valuable *in vitro* inhibitor of EZH2 [1]. The literature suggests that GSK126 may find greater relevance in alternative medical fields where EZH2 inhibition is required [1].
Given that EZH2 is explicitly recognized as an epigenetic regulator of cardiovascular development and diseases [2], and considering GSK126's proven efficacy in suppressing severe inflammation and pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6) [2], there is a strong mechanistic rationale for exploring GSK126 in the context of cardiovascular diseases and fibrosis. Chronic inflammation is a primary driver of fibrotic tissue remodeling in the cardiovascular system. Future research should focus on repurposing GSK126 for these non-oncological indications. Additionally, exploring combination therapies—such as pairing GSK126 with PI3K or MEK inhibitors—could help overcome known resistance pathways and enhance its therapeutic viability [1].
